Tilray Brands (TLRY) Cash from Financing Activities (2017 - 2026)
Tilray Brands (TLRY) posted Cash from Financing Activities of -$5.1 million for Q1 2026, down 110.66% on a QoQ basis from $48.1 million in Q4 2025, and down 128.38% year-over-year from $18.1 million in Q1 2025.
Tilray Brands (TLRY) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Tilray Brands' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 128.38% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $79.5 million (down 35.88% YoY) and the FY2025 annual result came in at $133.5 million, up 277.57% from the prior year.
- Cash from Financing Activities was -$5.1 million for Q1 2026 at Tilray Brands, down from $48.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $161.8 million in Q2 2022 and bottomed at -$85.4 million in Q4 2023.
- A 5-year average of $20.4 million and a median of $14.0 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 1639.86% — and 2024, when it sank 346.72%.
- Tilray Brands' Cash from Financing Activities stood at -$57.3 million in 2022, then sank by 49.1% to -$85.4 million in 2023, then jumped by 144.75% to $38.2 million in 2024, then gained by 25.91% to $48.1 million in 2025, then slumped by 110.66% to -$5.1 million in 2026.
- Business Quant data shows TLRY's Cash from Financing Activities at -$5.1 million in Q1 2026, $48.1 million in Q4 2025, and $19.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -5.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -5.13 Mn |
| Feb 28, 2026 | -5.13 Mn |
| Nov 30, 2025 | 48.10 Mn |
| Nov 30, 2025 | 48.10 Mn |
| Aug 31, 2025 | 19.85 Mn |
| Aug 31, 2025 | 19.85 Mn |
| May 31, 2025 | 16.64 Mn |
| May 31, 2025 | 16.64 Mn |
| Feb 28, 2025 | 18.07 Mn |
| Feb 28, 2025 | 18.07 Mn |
| Nov 30, 2024 | 38.20 Mn |
| Nov 30, 2024 | 38.20 Mn |
| Aug 31, 2024 | 60.59 Mn |
| Aug 31, 2024 | 60.59 Mn |
| May 31, 2024 | 7.07 Mn |
| May 31, 2024 | 7.07 Mn |
| Feb 29, 2024 | -10.91 Mn |
| Feb 29, 2024 | -10.91 Mn |
| Nov 30, 2023 | -85.37 Mn |
| Nov 30, 2023 | -85.37 Mn |